Stock Performance and Market Context
On 13 August 2026, Parmax Pharma Ltd’s stock price closed at Rs.115, setting a fresh 52-week and all-time high. The stock opened and traded consistently at this peak price throughout the day, demonstrating strong market conviction. This latest price represents a significant appreciation from its 52-week low of Rs.22.60, marking a substantial gain of 408.85% from the lowest point in the past year.
In comparison to broader market indices, Parmax Pharma has outperformed notably. The stock recorded a daily gain of 1.59%, while the Sensex declined by 0.22% on the same day. Over the past week, the stock surged 9.84%, contrasting with the Sensex’s 1.46% decline. The one-month return stands at an impressive 23.26%, while the three-month performance is even more striking at 259.38%, vastly outpacing the Sensex’s 4.27% gain in the same period.
Year-to-date, Parmax Pharma has delivered a remarkable 239.93% return, whereas the Sensex has fallen by 8.71%. Over the last year, the stock’s return of 218.12% starkly contrasts with the Sensex’s negative 3.40%. Even on a longer horizon, the three-year return of 277.05% significantly exceeds the Sensex’s 19.10% gain, while the five-year return of 142.36% remains robust despite the Sensex’s 40.34% growth. The stock’s ten-year return is recorded as zero, indicating a more recent emergence as a market performer.
Technical Indicators and Trend Analysis
Technical analysis confirms a bullish trend for Parmax Pharma Ltd. The current trend shifted to bullish on 7 August 2026 at a price level of Rs.106.75, moving from a previously mildly bullish stance. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the upward momentum.
Key technical indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullishness on both weekly and monthly timeframes. However, the Relative Strength Index (RSI) remains bearish, suggesting some caution regarding short-term overbought conditions. Immediate support is identified at the 52-week low of Rs.22.60, while resistance levels previously noted at Rs.105.28 (20-day moving average), Rs.58.43 (100-day moving average), and Rs.45.67 (200-day moving average) have been decisively surpassed with the stock now at Rs.115.
Delivery volumes have surged significantly, with a 1-month delivery change of 330.32% and a 1-day delivery change of 91.1% compared to the 5-day average, indicating increased investor participation in recent trading sessions.
Valuation and Financial Metrics
Despite the strong price performance, Parmax Pharma Ltd remains a micro-cap company with valuation metrics reflecting its current financial profile. The stock is loss-making, with no available price-to-earnings (P/E) ratio due to negative earnings. Price-to-book value stands at -6.89x, and enterprise value multiples such as EV/EBITDA and EV/EBIT are negative at -14.87x and -11.57x respectively. The EV/Sales multiple is 4.39x, while EV/Capital Employed is 11.28x. The PEG ratio is not applicable given the absence of positive earnings growth.
Dividend metrics are not applicable as the company has not declared dividends, with a dividend yield and payout ratio both at zero.
Quality Assessment and Financial Trends
Parmax Pharma Ltd’s overall quality grade is classified as below average, reflecting challenges in long-term financial performance. Management risk, growth, and capital structure are all rated below average. The company has experienced a 5-year sales decline of 14.30% and a significant 5-year EBIT contraction of 225.63%. The average EBIT to interest ratio is weak at 0.66x, although the company benefits from a net cash position with negative net debt and no promoter share pledging.
Return on capital employed (ROCE) and return on equity (ROE) are weak, at -28.89% and 5.12% respectively. The company maintains a tax ratio of 100%, with no dividend payouts and minimal institutional holdings.
Short-term financial trends remain negative as of March 2026, with net sales for the nine-month period at Rs.10.17 crores, reflecting a decline of 50.12%. Profit after tax (PAT) for the same period was a loss of Rs.3.39 crores, also down by 50.12%. Quarterly profit before tax excluding other income fell sharply by 265.08% to Rs.-2.30 crores. The debtors turnover ratio is at a low 3.83 times, indicating slower collections.
Summary of the Stock’s Journey to the All-Time High
Parmax Pharma Ltd’s ascent to Rs.115 represents a significant milestone, driven by sustained gains over the past week and month. The stock has recorded seven consecutive days of gains, delivering a 14.26% return during this period. This rally has been supported by strong technical signals and increased delivery volumes, reflecting heightened market activity.
While the company’s financial fundamentals present areas of concern, particularly in profitability and growth metrics, the stock’s price action highlights a distinct market valuation dynamic. The micro-cap status and loss-making profile contrast with the robust price appreciation, underscoring the complex interplay between market sentiment and company fundamentals in the Pharmaceuticals & Biotechnology sector.
Parmax Pharma Ltd’s achievement of an all-time high price is a noteworthy event in its market history, marking a phase of strong performance and investor engagement within a challenging financial backdrop.
